Sign in
CompletedNo phase

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Key facts

Who runs it
Nanjing Medical University
Where
China15 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
600 people enrolled
Started
1 Jul 2022
Ended
31 Jul 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
  • Blank control
Record updated
14 September 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset
  • Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled
  • The patients' age between 18 ~90 years old
  • Agree to participate in the study and sign the informed consent

Who cannot take part

  • Patients allergic to Thymosin α1
  • Patients with mental diseases, drug and alcohol dependence
  • Lactating women and pregnant women
  • Refuse to participate in this study and refuse to sign the informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

The 2 groups in the trial

  • Thymosin alpha 1Treatment being tested

    1.6 mg q12h for 5 days

    Treatment: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-

  • Blank controlOther group

    Standard care control; no placebo or sham thymosin alpha 1 injections were administered.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
14 September 2026